Avrupa Birliği - Almanca - EMA (European Medicines Agency)

leo pharma a/s - brodalumab - psoriasis - immunsuppressiva - kyntheum ist indiziert zur behandlung von mittelschwerer bis schwerer plaque-psoriasis bei erwachsenen patienten, die kandidaten für eine systemische therapie sind.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriasis - immunsuppressiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

madaus gmbh (8081848) - phytolacca americana (pot.-angaben); ammonium bromatum (pot.-angaben); sisymbrium officinale (pot.-angaben); paris quadrifolia (pot.-angaben) - mischung - teil 1 - mischung; phytolacca americana (pot.-angaben) (01983) 2,5 gramm; ammonium bromatum (pot.-angaben) (02124) 2,5 gramm; sisymbrium officinale (pot.-angaben) (15922) 2,5 gramm; paris quadrifolia (pot.-angaben) (19388) 2,5 gramm

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

kattwiga arzneimittel gmbh (8144649) - causticum hahnemanni (pot.-angaben); arisaema triphyllum (pot.-angaben); cuprum aceticum (pot.-angaben); ammonium bromatum (pot.-angaben); hydrastis canadensis (pot.-angaben); euspongia officinalis (pot.-angaben); hydrargyrum bichloratum (pot.-angaben); atropa bella-donna (pot.-angaben) - mischung flüssiger verdünnungen - teil 1 - mischung flüssiger verdünnungen; causticum hahnemanni (pot.-angaben) (01988) 3 gramm; arisaema triphyllum (pot.-angaben) (02029) 1 gramm; cuprum aceticum (pot.-angaben) (02035) 1 gramm; ammonium bromatum (pot.-angaben) (02124) 1 gramm; hydrastis canadensis (pot.-angaben) (02133) 1 gramm; euspongia officinalis (pot.-angaben) (02138) 1 gramm; hydrargyrum bichloratum (pot.-angaben) (02459) 1 gramm; atropa bella-donna (pot.-angaben) (20609) 1 gramm

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - medikamente zur behandlung von knochenerkrankungen - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karzinom, nicht kleinzellige lunge - antineoplastische mittel - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

İsviçre - Almanca - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - durvalumabum - konzentrat zur herstellung einer infusionslösung - durvalumabum 120 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 2.4 ml. - onkologikum - biotechnologika

İsviçre - Almanca - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - durvalumabum - konzentrat zur herstellung einer infusionslösung - durvalumabum 500 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 10 ml. - onkologikum - biotechnologika

İsviçre - Almanca - Swissmedic (Swiss Agency for Therapeutic Products)

kyowa kirin sàrl - burosumabum - injektionslösung - burosumabum 10 mg, histidinum, sorbitolum, polysorbatum 80, methioninum, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - x-chromosomaler hypophosphatämie (xlh) bei erwachsenen, jugendlichen und kindern ab 1 jahr - biotechnologika

İsviçre - Almanca - Swissmedic (Swiss Agency for Therapeutic Products)

kyowa kirin sàrl - burosumabum - injektionslösung - burosumabum 20 mg, histidinum, sorbitolum, polysorbatum 80, methioninum, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - x-chromosomaler hypophosphatämie (xlh) bei erwachsenen, jugendlichen und kindern ab 1 jahr - biotechnologika